Progressive Familial Intrahepatic Cholestasis and its Subtypes: The First Report From Iran

Background: Progressive familial intrahepatic cholestasis (PFIC) is a heterogeneous cholestatic disease (PFIC types 1, 2, and 3). Each type of the disease has different presentation, laboratory findings and prognosis. Up to now, there has been no report on the different types of this disease from Iran. Objectives: In this study, we have tried to uncover the frequencies and clinicopathologic presentations of three types of PFIC over four years (2010 - 2014) in Namazi hospital, which is affiliated with the Shiraz University of Medical Sciences and is the main hepatobiliary center in Southern Iran. Methods: During the above-mentioned four-year period, we studied 68 liver tissues taken from patients with a proven PFIC diagnosis, either in the form of a liver needle biopsy or explanted liver. Immunostaining was performed using three antibodies (ATP8B1, ABCB11, and ABCB4) on liver sections. Hematoxylin and eosin-stained sections were also reviewed. All of the demographics, clinical and paraclinical data were retrieved from the patients’ clinical charts. Results: Among these 68 PFIC cases, the most common type of PFIC in our center was found to be type 2 (50%), followed by type 1 (42.6%), with type 3 (7.4%) representing the least common. Pruritis and jaundice have been identified as the most common symptoms in all three groups; however, patients with PFIC type 3 showed older age with higher GGT levels. Conclusions: The two most common subtypes of PFIC in Iran are types 2 and 1, similar to some areas in the West. Immunostaining can accurately subclassify patients with PFIC.

[1]  N. Ehsan,et al.   Hepatic immunohistochemistry of bile transporters in progressive familial intrahepatic cholestasis. , 2016, Annals of hepatology.

[2]  F. Callea,et al.  Genetics and Molecular Modeling of New Mutations of Familial Intrahepatic Cholestasis in a Single Italian Center , 2015, PloS one.

[3]  S. Mousavi,et al.  Partial Internal Biliary Diversion in Progressive Familial Intrahepatic Cholestasis: Introduction of a New Approach , 2014, Hepatitis monthly.

[4]  A. Bidari,et al.  Biopsy-driven diagnosis in infants with cholestatic jaundice in Iran. , 2014, World journal of gastroenterology.

[5]  D. Owczarek,et al.  Inflammatory bowel disease: epidemiology, pathology and risk factors for hypercoagulability. , 2014, World journal of gastroenterology.

[6]  S. Dehghani,et al.  Etiology and Complications of Liver Cirrhosis in Children:Report of a Single Center from Southern Iran , 2013, Middle East journal of digestive diseases.

[7]  F. Callea,et al.  Two novel mutations in African and Asian children with progressive familial intrahepatic cholestasis type 3. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[8]  P. Rosenthal,et al.  Morphologic Findings in Progressive Familial Intrahepatic Cholestasis 2 (PFIC2): Correlation With Genetic and Immunohistochemical Studies , 2011, The American journal of surgical pathology.

[9]  D. Consonni,et al.  Clinical Features and Genotype-Phenotype Correlations in Children With Progressive Familial Intrahepatic Cholestasis Type 3 Related to ABCB4 Mutations , 2011, Journal of pediatric gastroenterology and nutrition.

[10]  B. Stieger,et al.  ATP8B1 and ABCB11 analysis in 62 children with normal gamma‐glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): Phenotypic differences between PFIC1 and PFIC2 and natural history , 2010, Hepatology.

[11]  R. Houwen,et al.  Liver disease associated with canalicular transport defects: current and future therapies. , 2010, Journal of hepatology.

[12]  K. Setchell,et al.  Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy. , 2009, Gastroenterology.

[13]  K. McColl,et al.  Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. , 2009, Gastroenterology.

[14]  F. Mahjoub,et al.  Liver needle biopsy in Iraninan pediatric patients: diagnostic significance and pattern of liver diseases. , 2009, Indian journal of pathology & microbiology.

[15]  H. Hsu,et al.  Diagnosis of BSEP/ABCB11 mutations in Asian patients with cholestasis using denaturing high performance liquid chromatography. , 2008, The Journal of pediatrics.

[16]  H. Tilg,et al.  W1138 A Nationwide Multicenter Study On Venous Thromboembolism in Inflammatory Bowel Disease , 2008 .

[17]  Richard J. Thompson,et al.  Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. , 2008, Gastroenterology.

[18]  L. Pawlikowska,et al.  Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport , 2006, Hepatology.

[19]  M. Hadchouel,et al.  Evidence for defective primary bile acid secretion in children with progressive familial intrahepatic cholestasis (Byler disease) , 1994, European Journal of Pediatrics.

[20]  Richard J. Thompson,et al.  Characterization of mutations in ATP8B1 associated with hereditary cholestasis , 2004, Hepatology.

[21]  L. Frulloni,et al.  Progressive familial intrahepatic cholestasis. , 2002, Acta bio-medica : Atenei Parmensis.

[22]  R. Houwen,et al.  FIC1, the protein affected in two forms of hereditary cholestasis, is localized in the cholangiocyte and the canalicular membrane of the hepatocyte. , 2001, Journal of hepatology.

[23]  Y. Jeng,et al.  Progressive Familial Intrahepatic Cholestasis with High γ-Glutamyltranspeptidase Levels in Taiwanese Infants: Role of MDR3 Gene Defect? , 2001, Pediatric Research.

[24]  P. Bosma,et al.  The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. , 2001, Gastroenterology.

[25]  E. Jacquemin,et al.  Progressive familial intrahepatic cholestasis. Genetic basis and treatment. , 2000, Clinics in liver disease.

[26]  Richard J. Thompson,et al.  Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. , 1999, Gastroenterology.

[27]  E. Jacquemin.  Progressive familial intrahepatic cholestasis , 1999, Journal of gastroenterology and hepatology.

[28]  P. Bosma,et al.  Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  C. Riely,et al.  Normal serum gamma-glutamyl-transpeptidase activity identifies groups of infants with idiopathic cholestasis with poor prognosis. , 1987, The Journal of pediatrics.